
GLP-1s
GLP-1 Microdosing
Microdosing means taking a GLP-1 — glucagon-like peptide-1 receptor agonists, the class that includes semaglutide and tirzepatide — at a low dose on purpose, below the usual target.
It's caught on with health-minded people who want the upside — a steadier appetite, a gentler experience, maybe a longevity edge — without going all in on a full dose.
The open question is a simple one: what does a low dose do? That's the part nobody has pinned down yet.
- Reading time
- 5 min
- Source last reviewed
- 4 Jun 20264 Jun 2026
- Last updated
- 4 Jun 20264 Jun 2026
You've probably seen it framed as the insider move — fit, healthy people taking a little Ozempic to stay sharp, hold a weight, or buy into the longevity story without the full-dose commitment.
It's an appealing idea: a gentler, cheaper, more tailored way to use a drug that clearly works.
The catch is that the low dose itself is the part nobody has pinned down.
What microdosing means
Every standard GLP-1 prescription already starts low. You begin at a small dose so your body can adjust, then step up every few weeks toward a target.
In the SELECT trial, semaglutide started at 0.24 mg a week and climbed to its 2.4 mg target by week 16 3.
That climb is called titration, and the small early doses are a stepping stone, not the destination.
Microdosing keeps the dose low instead of climbing — you settle at a small amount and stay there.
There's no official version of it; "microdosing" is a term that grew up around telehealth and online communities, not a dose written into a trial 6.
People do it with both of the major molecules — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Zepbound and Mounjaro).
For how a standard course is started and stepped up, see How to Start GLP-1s.
Why people try it
Four motivations drive the practice, and each makes real-world sense.
Cost is the most common.
Even at discounted prices, the branded full-dose drugs stay out of reach for a lot of people, so a smaller dose stretched further looks like a way in 7.
Side effects are the next: the nausea and gut upset GLP-1s are known for show up mostly during the climb to a full dose — worst at the start and at each step up 23 — so the hope that a low, steady dose feels gentler has real physiology behind it.
Maintenance is a third pull — taking just a little to hold a result after reaching a goal, rather than stopping cold.
The fourth is the longevity story: the biohacker frame that a small, steady dose might tune your metabolism and add healthy years, the same optimization pitch that surrounds metformin and rapamycin.
The aging science behind that frame is its own subject; for what the trials show there, see GLP-1s and Healthy Aging.
Wanting a cheaper, gentler, more sustainable version of a drug you've watched work isn't naive — it's sensible. The appeal is real.
It just isn't the same thing as knowing the low dose delivers.

What a low dose does — and what we don't know yet
Start with the fair version. A lower dose almost certainly does something — less drug still nudges appetite, just more gently.
The honest gap is that no one has studied a deliberate low-dose-and-stay approach.
Every trial that built these drugs' reputation used the full, titrated dose 123.
And within those trials, more drug meant more effect: in SURMOUNT-1, tirzepatide produced about 15% weight loss at 5 mg and about 21% at 15 mg 2.
So a much smaller dose most likely does proportionally less — not the same result for less money.
That doesn't mean microdosing doesn't work. It means it hasn't been measured.
The specific claims you'll see attached to it — that a microdose sharpens metabolism, lowers inflammation, even protects the brain — are extrapolations from full-dose research, not things anyone has tested at a small dose 6.
The full-dose evidence picture lives at GLP-1s and Longevity. The open question here is narrower and more honest: whether a low dose carries any of that over.
Right now, we don't know — and that's worth saying plainly rather than dressing up either way.
How people get it
Because there's no standard microdose, the supply is almost entirely compounded — a pharmacy mixing the drug to order rather than dispensing the manufactured pen — usually through telehealth 4.
That route exists partly because of how the shortages played out: the tirzepatide and semaglutide shortages were declared resolved in late 2024 and early 2025, which narrowed the room for large-scale compounding, though a smaller compounding market remains 4.
The practical thing to know is that compounded vials aren't standardized the way a branded pen is, so the dose you end up with depends on the product and on measuring it yourself — and the FDA has noted dosing mistakes when people self-measure compounded semaglutide 5.
None of that makes microdosing reckless.
It's the reason it's worth doing with a clinician who can set the dose and the source, rather than working it out alone from a vial.
So is microdosing worth it?
Put it together and microdosing is easy to understand and genuinely appealing — cheaper, gentler, and tied to a longevity story a lot of us find compelling.
The one honest caveat is that the low dose itself hasn't been studied, so what it delivers is still an open question rather than a settled answer.
That's not a reason to wave it off — it's a reason to go in clear-eyed.
Microdosing is a real, understandable practice — the appeal is solid; the proof at a small dose just isn't in yet.
If you're curious about it, that's a good thing to take to someone who knows your situation.
Sources and references7 sources
- 1
Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021. PubMed ↑
- 2
Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022. PubMed ↑
- 3
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023. PubMed ↑
- 4
"FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize." U.S. Food and Drug Administration. 2026. FDA ↑
- 5
"FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products." U.S. Food and Drug Administration. 2024. FDA ↑
- 6
Palmer K. "Microdosing aims to extend the lifespan of the GLP-1 compounding market." STAT. 2025. STAT ↑
- 7
Palmer K, Chen E. "The end of compounded GLP-1 copies leaves many patients in a 'lose-lose' position." STAT. 2025. STAT ↑
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint